BiotechTube
Home/Syngle Therapeutics/Guus Scheefhals
GS

Guus Scheefhals

Chief Executive Officer

Syngle Therapeutics

Therapeutic Areas

Parkinson's DiseaseSynucleinopathies

Syngle Therapeutics Pipeline

DrugIndicationPhase
26F1 AAV Gene TherapyParkinson's DiseasePreclinical

Leadership Team at Syngle Therapeutics

VV
Victor van Koolwijk
Chief Financial Officer
DB
Dr. Bas Blits
Head of R&D / CSO (implied)
View full Syngle Therapeutics profile